Hematology/Oncology Clinics of North America. 2005 Dec;19(6):1137-45. [Link]
Dowell JE, Kindler HL.
University of Texas-Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8852, USA; Division of Hematology & Oncology, Dallas Veterans Affairs Medical Center, Dallas, TX, USA.
A large body of preclinical evidence suggests that angiogenesis plays a key role in the pathogenesis of malignant mesothelioma. Several mediators of angiogenesis seem to be autocrine growth factors in mesothelioma, and in preclinical models, agents that target angiogenesis produce tumor regression. Several clinical trials are currently evaluating the efficacy of inhibitors of angiogenesis in mesothelioma. This article details the preliminary results of these trials and future directions.